Can I Get GLP-1 If I'm Not Diabetic? What You Need to Know
The short answer
No, GLP-1 medications are not only for people with diabetes. In fact, the majority of GLP-1 medication users do not have type 2 diabetes. This page explains why the confusion exists, who actually qualifies for these medications, and what the clinical data shows about who is using them today.
Why the confusion: the history of GLP-1 medications
The assumption that GLP-1s are “just for diabetics” comes from their origins. The story makes sense: GLP-1 receptor agonist medications were originally developed and FDA-approved specifically for type 2 diabetes management.
Branded semaglutide came to market in 2017 for type 2 diabetes. Branded tirzepatide arrived in 2022, also approved for type 2 diabetes. For years, these medications were talked about and prescribed within the diabetes space.
But then something changed.
Providers and patients noticed that people taking these diabetes medications for weight management were experiencing significant weight loss. Researchers designed clinical trials specifically examining whether these medications could help people lose weight without a diabetes diagnosis. The data was clear.
In 2021, the FDA approved a branded version of semaglutide[1] specifically for chronic weight management in adults without diabetes. In 2023, a branded version of tirzepatide[2] received FDA approval for the same purpose.
The diabetes association persists because these medications have been around longer in the diabetes context. But the weight management indication was studied, approved, and is now a core use case. You do not need a diabetes diagnosis to be prescribed a GLP-1 medication.
Who actually uses GLP-1 medications today
The clinical picture has shifted dramatically in the past 18 months.
According to research from RAND published in 2025[4], the majority of GLP-1 users are people without type 2 diabetes. Women represent approximately 80% of non-diabetic GLP-1 users. Perimenopausal women (ages 35-50) are the largest single user cohort.
This is not because people without diabetes are finding a loophole in a drug intended for diabetics. This is the intended use case. The medication was studied, approved, and is now prescribed most frequently for people exactly like you.
The actual FDA approval criteria
FDA approval for GLP-1 weight management medications applies to adults who meet either of two conditions[3]:
Condition 1: BMI of 30 or higher (regardless of other health factors)
Condition 2: BMI of 27 or higher, plus at least one weight-related health condition
The weight-related health conditions that count include:
- High blood pressure (hypertension)
- Elevated cholesterol or other lipid abnormalities
- Pre-diabetes or metabolic syndrome
- Type 2 diabetes (if you have it)
- Heart disease risk factors
Notice what is not on this list: you do not need a type 2 diabetes diagnosis. You do not need to have failed diet and exercise (although research suggests most people have). The approval is based on BMI and cardiometabolic risk.
Compounded versions of semaglutide and tirzepatide are prescribed by your provider using similar clinical criteria. The provider reviews your health history, lab work, and current BMI to determine whether treatment is medically appropriate.
Why this matters if you are perimenopausal
The perimenopausal years (typically 40-55) are a biological turning point that many women do not anticipate. Estrogen decline does two critical things to your metabolism:
First, it shifts where your body stores fat. Before perimenopause, fat is distributed toward the hips and thighs. During perimenopause, estrogen decline causes visceral fat redistribution to the midsection and abdomen. Visceral fat is metabolically active and increases insulin resistance and cardiovascular risk, even in people without a diabetes diagnosis.
Second, estrogen decline intensifies appetite signaling. Researchers call this “food noise.” The mental urge to eat becomes more intrusive, and satiety signals become less reliable. This is not a willpower problem. It is a biological shift in how your brain regulates hunger hormones.
GLP-1 mechanisms specifically address both of these pathways. These medications reduce appetite signaling and improve insulin sensitivity, which is particularly relevant for women navigating the metabolic changes of perimenopause.
The Endocrine Society and researchers publishing in the New England Journal of Medicine have examined GLP-1 effects specifically in pre- and perimenopausal women[5]. The data supports their use in this population for weight management, independent of a diabetes diagnosis.
Up to 70% of women experience weight gain during the menopause transition[5]. That shift is not a failure. It is biology. GLP-1 medications address that biology directly.
How you find out if you qualify at Transformation Health
Getting evaluated is straightforward. You complete a brief online intake form that covers:
- Your current height and weight (to calculate BMI)
- Your medical history (including blood pressure, cholesterol, pre-diabetes status, or other health conditions)
- Your current medications
- Your goals
An independent, licensed provider reviews your information within 24 hours. The provider determines whether GLP-1 treatment is medically appropriate for your specific situation.
You do not need a phone call. You do not need an in-person office visit. You do not need to prove you have tried and failed at other methods. The provider makes the determination based on your health history and current clinical picture.
If the provider determines that a GLP-1 medication is appropriate, your prescription is filled by a licensed US compounding pharmacy and shipped to your door. If the provider determines that it is not appropriate right now, they can explain why and discuss what might change that determination.
Compounded vs. FDA-approved medications: what you should know
Transformation Health provides access to licensed prescribers that will write personalized compounded semaglutide and tirzepatide prescriptions. These are prepared by US-based, state-licensed compounding pharmacies.
Compounded medications are not FDA-approved. This does not mean they are unsafe or ineffective, but it does mean they have not undergone the independent review process that FDA-approved branded GLP-1 medications have. They are not the same products.
Your provider will review your health history and determine which formulation, if any, is appropriate for you. The clinical decision is always made by the prescribing provider, not by Transformation Health.
If you have pre-diabetes or other weight-related conditions
Pre-diabetes, metabolic syndrome, elevated cholesterol, and high blood pressure are all qualifying conditions for GLP-1 weight management medications. Having one or more of these does not require a diabetes diagnosis. In fact, these conditions are often why someone is a good candidate for GLP-1 treatment.
GLP-1 medications improve insulin sensitivity and help regulate metabolic function. For people with pre-diabetes, these effects can help prevent the progression to type 2 diabetes while also supporting weight loss.
Your provider will consider your full clinical picture: your BMI, your lab work, your blood pressure, your metabolic markers, and your health goals. All of these factors go into the decision.
The bottom line
GLP-1 medications were approved for weight management in people without type 2 diabetes because the evidence supported that use. You do not need a diabetes diagnosis. A BMI over 30, or a BMI over 27 with at least one weight-related health condition, is enough to be evaluated.
The majority of GLP-1 users are people like you. Women, perimenopausal, dealing with the biological shifts that come with aging, ready to address them with medical support.
If you have been hesitating because you thought GLP-1s were not for you, this is the moment to find out whether you qualify.
Citations
[1] FDA. “FDA Approves New Drug Treatment for Chronic Weight Management in Adults.” Press Release. June 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
[2] FDA. “Prescribing Information for tirzepatide for chronic weight management.” FDA-approved product labeling. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
[3] FDA. “GLP-1 Receptor Agonists: FDA Obesity Medications.” Drugs Approved to Treat Obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[4] Raatz H, et al. “GLP-1 Receptor Agonist Use in the United States: Epidemiology and Demographics.” RAND Health Research. 2025.
[5] Endocrine Society. “Hormonal Management of Women Across the Lifespan.” Clinical Practice Guidelines. 2021.
Important: Compounded medications are not FDA-approved products. They are prepared by US-based, state-licensed compounding pharmacies and have not been independently evaluated by the FDA for safety, efficacy, or quality. FDA approval information referenced on this page applies to FDA-approved branded GLP-1 medications only. All prescriptions require evaluation by an independent, licensed healthcare provider. Eligibility is determined by the prescribing provider based on your health history. Not all patients will qualify.